U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT07508761) titled 'IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors' on March 23.
Brief Summary: Phase 1/2 Study for IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: IPG7236
IPG7236: Part A: 500 mg BID or 800 mg BID, the dose in Part B is the RP2D confirmed in Part A, Oral (fasting: 1 hour before meal or 2 hours after meal, every 12±2 hours), Continuous daily administration, 21-day treatment cycle,Until disease progression, unacceptable toxicity, withdrawal of consent, or other reas...